ArticleFrontiers in pharmacology2021

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance.

Qingli Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.